Prosecution Insights
Prosecution Insights
18 pending office actions • 12 clients • 16 examiners • 11 art units • 0 of 18 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (6%) |
| §103 only | 2 (11%) |
| Double-patenting + other | 6 (33%) |
| Multi-statute (no §101) | 8 (44%) |
| No statute on record | 1 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRAUN, MADELINE E | 2 | 67.9% | +25.4% |
| FAUST, AMBER KATHLEEN | 2 | 60.3% | +53.6% |
| WILLIS, DOUGLAS M | 1 | 82.4% | +19.5% |
| KUCKLA, ANNA GRACE | 1 | 50.0% | +53.3% |
| YOUNGBLOOD, WILLIAM JUSTIN | 1 | 61.9% | +40.0% |
| CLARK, AMY LYNN | 1 | 39.1% | +30.9% |
| FOWLER, ALAN JEROME | 1 | 100.0% | +0.0% |
| HUI, SAN MING R | 1 | 59.3% | +19.9% |
| GODDARD, LAURA B | 1 | 50.9% | +14.1% |
| WHITE, DAWANNA SHAR-DAY | 1 | 62.8% | +19.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17806689 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | SIMMONS, CHRIS E | 15d overdue |
| 18255855 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SHOWALTER, ALEXANDER KEITH | 9d overdue |
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | BRAUN, MADELINE E | 5d |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | CLARK, AMY LYNN | 84d |
| 18724480 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BRAUN, MADELINE E | — |
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | WILLIS, DOUGLAS M | — |
| 18542629 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KUCKLA, ANNA GRACE | — |
| 18505975 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | FOWLER, ALAN JEROME | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | BRAUN, MADELINE E | 5d |
| 18542628 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | YOUNGBLOOD, WILLIAM JUSTIN | 71d |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | CLARK, AMY LYNN | 84d |
| 18724480 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BRAUN, MADELINE E | — |
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | WILLIS, DOUGLAS M | — |
| 18578300 | METHODS OF TREATING NEUROLOGICAL DISEASES | FAUST, AMBER KATHLEEN | — |
| 18542629 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | KUCKLA, ANNA GRACE | — |
| 18552482 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | HUI, SAN MING R | — |
| Art Unit | Apps |
|---|---|
| 1624 | 3 |
| 1629 | 2 |
| 1627 | 2 |
| 1643 | 2 |
| 1626 | 1 |
| 1628 | 1 |
| 1691 | 1 |
| 1642 | 1 |
| 1616 | 1 |
| 1644 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18724480 | BICYCLIC QUINONES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Ic-Medtech Corp. | BRAUN, MADELINE E | §102§112 | Non-Final OA | — | Pending | Jun 26, 2024 | |
| 18626823 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | WILLIS, DOUGLAS M | 1624 | §102§112 | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18578300 | METHODS OF TREATING NEUROLOGICAL DISEASES | Sinomab Bioscience Limited | FAUST, AMBER KATHLEEN | §102§103§112DP | Non-Final OA | — | Pending | Jan 10, 2024 | |
| 18542629 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | KUCKLA, ANNA GRACE | 1626 | §102§112 | Non-Final OA | — | Pending | Dec 16, 2023 |
| 18542628 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | YOUNGBLOOD, WILLIAM JUSTIN | 1629 | §102§112DPOther | Non-Final OA | 71d | Pending | Dec 16, 2023 |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | Vivavision Biotech, Inc. | CLARK, AMY LYNN | 1628 | §102§112 | Non-Final OA | 84d | Pending | Nov 16, 2023 |
| 18505975 | INDENE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | NucMito Pharmaceuticals Co., Ltd. | FOWLER, ALAN JEROME | 1691 | §102§112 | Non-Final OA | — | Pending | Nov 09, 2023 |
| 18552482 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | HUI, SAN MING R | 1627 | §103 | Non-Final OA | — | Pending | Sep 26, 2023 |
| 18552381 | FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Anwita Biosciences, Inc. | GODDARD, LAURA B | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Sep 25, 2023 |
| 18550960 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | WHITE, DAWANNA SHAR-DAY | 1627 | §103§112DP | Non-Final OA | — | Pending | Sep 16, 2023 |
| 18547018 | CRYPTOPHYCIN COMPOUNDS AND CONJUGATES THEREOF | Universitat Bielefeld | BRAUN, MADELINE E | 1624 | §101§102§103§112 | Non-Final OA | 5d | Pending | Aug 18, 2023 |
| 18258209 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | Shanghai Ruotuo Biosciences Co., Ltd. | CANELLA, KAREN A | 1643 | §102§103§112 | Non-Final OA | — | Pending | Jun 18, 2023 |
| 18256636 | PDE4 DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | MCDOWELL, BRIAN E | 1624 | — | Final Rejection | — | Pending | Jun 09, 2023 |
| 18255855 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | Eubulus Biotherapeutics Inc. | SHOWALTER, ALEXANDER KEITH | 1629 | §102§103 | Final Rejection | 9d overdue | Pending | Jun 02, 2023 |
| 18253455 | DRY POWDER ANTIVIRAL COMPOSITIONS AND THEIR USE FOR TREATING VIRAL INFECTION | Nano Pharmasolutions, Inc. | SAEED, ALI S | 1616 | §102§103DP | Final Rejection | — | Pending | May 18, 2023 |
| 18174565 | COMPOSITIONS AND METHODS OF CELLULAR IMMUNOTHERAPY | Crage Medical Co., Limited | BELYAVSKYI, MICHAIL A | 1644 | §103 | Final Rejection | 393d overdue | Pending | Feb 24, 2023 |
| 18020140 | ENGINEERED CELLS AND METHOD FOR ENGINEERING CELLS | Carsgen Life Sciences Co., Ltd. | FAUST, AMBER KATHLEEN | 1643 | §103§112DP | Final Rejection | — | Pending | Feb 07, 2023 |
| 17806689 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | Ic-Medtech Corp. | SIMMONS, CHRIS E | 1622 | §102§103§112 | Final Rejection | 15d overdue | Pending | Jun 13, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial